Benralizumab recalls
The FDA has published 1 recall involving Benralizumab since 2025. The latest was reported on 22 Oct 2025. Most were for sterility. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls1since 2025
Last 12 months0reported
Class I00% of total
Ongoing1latest 22 Oct 2025
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 1 100%Class III 0 0%
Why benralizumab is recalled
Companies
By year
Ongoing benralizumab recalls
1 active| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Fasenra (benralizumab) Injection, 30 mg/mL recalledFasenra | Astrazeneca Pharmaceuticals | Sterility | Nationwide |
All benralizumab recalls, newest first
1 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Fasenra (benralizumab) Injection, 30 mg/mL recalledFasenra | Astrazeneca Pharmaceuticals | Sterility | Nationwide |
Should you stop taking Benralizumab?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.